Clinical Study on the Combination of Levetiracetam and Oxcarbazepine in the Treatment of Childhood Refractory Epilepsy
Objective To explore the clinical efficacy of the combination of levetiracetam and oxcarbazepine in the management of childhood refractory epilepsyy(CRE).Methods Clinical data of 68 cases of CRE admitted to Guangdong Maternal and Child Health Hospital from January 2022 to January 2024 were retrospectively analyzed.Accorded to different treatment methods,they were divided into control group and observation group,with 34 cases in each group.The control group was treated with oxcarbazepine,the observation group was treated with levetiracetam in combination.The therapeutic efficacy,clinical symptoms,serological indicators,quality of life,and safety were evaluated after the treatment course.Results The total effective rate of the observation group was 94.12%(32/34),which was higher than 76.47%(26/34)of the control group,and the difference was statistically significant(P<0.05).After treatment,the seizure frequency of the observation group was 1.00(1.00,1.00)times/month,which was lower than 2.00(1.00,2.00)times/month of the control group,and the seizure duration of the observation group was(4.71±1.22)min/times,which was shorter than(8.29±2.06)min/times of the control group,the differences were statistically significant(P<0.05).Serum neuron specific enolase(NSE)and interleukin-6(IL-6)levels in the observation group were(9.30±1.73)μg/L and(3.44±0.74)pg/mL,respectively,which were lower than(14.50±2.55)μg/L and(7.03±1.35)pg/mL of control group,and the differences were statistically significant(P<0.05).The score of quality of life childhood epilepsy(QOLCE)in the observation group was(82.30±6.05)points,which was higher than(76.70±7.51)points in the control group,and the difference was statistically significant(P<0.05).No serious adverse reactions occurred in the two groups,which did not affect the continuation of the treatment regimen.Conclusion The efficacy of levetiracetam combined with oxcarbazepine in treating CRE is superior to the monotherapy of oxcarbazepine.It can significantly ameliorate the clinical symptoms of children,down-regulate the levels of serum NSE and IL-6,enhance the quality of life of children with high safety.
childhood refractory epilepsyoxcarbazepinelevetiracetamcurative effectneuron sepecific enolaseinterleukinquality of life
万方数据
维普
